Wegovy eased osteoarthritis knee pain in people with obesity: study

Semaglutide, higher often called Ozempic and Wegovy, helped alleviate ache from knee osteoarthritis and enhance operate in sufferers with extreme weight problems, a brand new examine discovered.

The outcomes of the 68-week trial have been printed within the New England Journal of Drugs, and will pave the best way for a future FDA approval of GLP-1 receptor agonists for the joint-degrading situation.

GLP-1 medicine have revolutionized weight problems therapy, however analysis suggests they may additionally assist deal with circumstances as assorted as coronary heart illness, habit and sleep apnea. Novo Nordisk, the maker of Wegovy, might have funded the most recent trial to see if knee osteoarthritis could be added to that rising checklist of non-obesity indications — and assist the drug get broader insurance coverage protection.